MEDICATION DRUG

Classificatio n

INDICATION/ CONTRAINDICATI ON

MECHANISM OF ACTION
Anthranilic acid derivative. Like ibuprofen inhibits prostaglandin synthesis and affects platelet function. No evidence that it is superior to aspirin.

DOSING & ADMINISTRATION

Mild to Moderate Pain adult: PO Loading Dose 500 mg PO Maintenance Dose 250 mg q6h prn Administration Oral

ADVERSE EFFECT

NURSING RESPONSIBILITIES
Assess patients who develop severe diarrhea and vomiting for dehydration and electrolyte imbalance. Lab tests: With long-term therapy (not recommended) obtain periodic complete blood counts, Hct and Hgb, and kidney function tests. Discontinue drug promptly if diarrhea, dark stools, hematemesis, ecchymoses, epistaxis, or rash occur and do not use again. Contact physician. Notify physician if

Generic Name: Mefenamic Acid Brand Name: Ponstan, Ponst el

central nervous system agen t;analgesic; nsaid; antipyretic Pregnancy Category:C

Hypersensitivity to drug;GI inflammation,or ulceration.Safety in children <14 y, during pregnancy (category C), or lactation is not established.

CNS: Drowsiness, insomnia, dizziness, nervousness, confusion, headache. GI: Severe diarrhea, ulceration, and bleeding; nausea, vomiting, abdominal cramps, flatus, constipation, hepatic toxicity. Hematologic: Prolonged prothrombin time, severe autoimmun e hemolytic anemia (long-term use), leukopenia, eosinophilia,

agranulocytosis, thrombocytopenic purpura, megaloblastic anemia, pancytopenia,bon e marrow hypoplasia. Urogenital: Nephrotoxicity, dysuria, albuminuria, hematuria, elevation of BUN. Skin: Urticaria, rash, facial edema. Spec Senses: Eye irritation, loss of color vision (reversible), blurred vision, ear pain. Body Whole: Perspiration. CV: Palpitation. Respiratory: Dyspnea; acute exacerbation of asthma;

persistent GI discomfort, sore throat, fever, or malaise occur. Do not drive or engage in potentially hazardous activities until response to drug is known. It may cause dizziness and drowsiness. Monitor blood glucose for loss of glycemic control if diabetic. Do not breast feed while taking this drug without consulting physician.

bronchoconstricti on (in patients sensitive to aspirin).

MEDICATION DRUG

Classificatio n
Antibiotic, Cephalospori n (first generation) Pregnancy Category B

INDICATION/ CONTRAINDICATIO N
Indications Respiratory tract infections caused by S. pneumoniae, g roup A betahemolytic streptococci Dermatologic infections caused by staphylococci, streptococci Otitis media caused by S. pneumoniae, H. influenzae,strep tococci, staphylococci, M. c atarrhalis Bone infections caused

MECHANISM OF ACTION
Bactericidal: inhibits synthesis of bacterial cell wall, causing cell death.

DOSING & ADMINISTRATION

Adults 14 g/day in divided doses; 250 mg PO q 6 hr usual dose.

ADVERSE EFFECT

NURSING RESPONSIBILITIES
Arrange for culture and sensitivity tests of infection before and during therapy if infection does not resolve. Give drug with meals; arrange for small, frequent meals if GI complications occur. Refrigerate suspension, discard after 14 days.

GENERIC NAME: cephalexin Brand Name: Ap oCephalex (CA N), Biocef, Ke flex, NovoLexin(CAN), N uCephalex (CA N), PMSCephalexin (C AN), cephalexi nhydrochlorid e monohydrate, Biocef, Keftab

Adverse effects Headache, dizziness, lethargy, paresthe sias, Nausea, vomiting, diarrhea, anorexia, abdominal pain, flatulence, pseudomembranou s colitis, liver toxicity, Nephroto xicity, Bone marrow depression, Rangin g from rash to fever to a naphylaxis;serum sickness reaction, Superinf ections

Skin and skin structure infections: 500 mg PO q 12 hr. Larger doses may be needed in severe cases; do not exceed 4 g/day.

Pediatric Patients 2550 mg/kg/day PO in divided doses.

by staphylococci, P. mirabilis GU infections caused by E. coli, P. mirabilis, Klebsiella Contraindication Allergy to cephalosporins o r penicillins; renal failure; lactation, pregnancy

Skin and skin structure infections: Divide total daily dose, and give q 12 hr. Dosage may be doubled in severe cases. Otitis media: 75 100 mg/kg/day PO in four divided doses.